Tong Sabine, Amand Caroline, Kieffer Alexia, Kyaw Moe H
IVIDATA Stats, 79 Rue Baudin, 92300, Levallois-Perret, France.
Sanofi, 1 Avenue Pierre Brossolette, 91380, Chilly-Mazarin, France.
BMC Health Serv Res. 2018 Sep 14;18(1):715. doi: 10.1186/s12913-018-3529-4.
Pneumonia is the leading cause of morbidity and mortality worldwide. Pneumococcal conjugate vaccines have reduced the burden of pneumonia, but data on the current burden of pneumonia and its impact on the healthcare system are needed to inform the development and use of new vaccines and other preventive measures.
We retrospectively analyzed the frequency of pneumonia in the US during 2008-2014 using data from the MarketScan® Commercial Claims and Encounters database. Frequencies of healthcare utilization related to the index pneumonia episode were calculated using the annual number of enrolled person-years (PY) as the denominator and the number of individuals with pneumonia as the numerator. Pneumonia-associated costs were calculated as mean payment per episode during the 2 years from 2013 to 2014.
The overall annual healthcare utilization rate for pneumonia was 15.1 per 1000 PY and decreased slightly from 2008 to 2014 (from 15.4 to 13.5 per 1000 PY). Most pneumonia-related healthcare utilization was due to office/outpatient visits (10.3 per 1000 PY; 68.3%). Emergency department/urgent care visits (2.5 per 1000 PY; 16.9%) and hospitalizations (2.2 per 1000 PY; 14.8%) contributed less. Pneumonia-related healthcare utilization was highest in children < 5 years (rate per 1000 PY = 29.7 for < 1 year, 47.9 for 1 year, and 39.5 for 2-4 years) and adults > 65 years (45.0 per 1000 PY). The mean cost per pneumonia episode (95% confidence interval) was US$429.1 ($424.8-$433.4) for office/outpatient visits, $1126.9 ($1119.5-$1134.3) for emergency department/urgent care visits, and $10,962.5 ($10,822.8-$11,102.2) for hospitalization.
The burden of pneumonia on the US healthcare system remains substantial. The results presented here can help guide new vaccination strategies and other preventive interventions for reducing the remaining burden of pneumonia.
肺炎是全球发病和死亡的主要原因。肺炎球菌结合疫苗减轻了肺炎负担,但需要有关当前肺炎负担及其对医疗保健系统影响的数据,以为新疫苗和其他预防措施的研发及应用提供参考。
我们使用MarketScan®商业索赔和就诊数据库的数据,回顾性分析了2008 - 2014年美国肺炎的发病频率。以年度参保人年数(PY)为分母、肺炎患者人数为分子,计算与首次肺炎发作相关的医疗保健利用率。肺炎相关费用按2013年至2014年这两年间每次发作的平均支付费用计算。
肺炎的总体年度医疗保健利用率为每1000 PY 15.1例,2008年至2014年略有下降(从每1000 PY 15.4例降至13.5例)。大多数与肺炎相关的医疗保健利用是由于门诊/门诊就诊(每1000 PY 10.3例;68.3%)。急诊/紧急护理就诊(每1000 PY 2.5例;16.9%)和住院治疗(每1000 PY 2.2例;14.8%)的占比相对较小。肺炎相关的医疗保健利用在5岁以下儿童中最高(<1岁儿童每1000 PY发病率为29.7例,1岁儿童为47.9例,2 - 4岁儿童为39.5例)以及65岁以上成年人中(每1000 PY 4D.0例)。门诊/门诊就诊的每次肺炎发作平均费用(95%置信区间)为429.1美元(424.8 - 433.4美元),急诊/紧急护理就诊为1126.9美元(1119.5 - 1134.3美元),住院治疗为10962.5美元(10822.8 - 11102.2美元)。
肺炎对美国医疗保健系统的负担仍然很大。此处呈现的结果有助于指导新的疫苗接种策略和其他预防干预措施,以减轻肺炎的剩余负担。